Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems’ activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back pain, improving back function and increasing health-related quality of life. Further, at five years, 95% of activL subjects were re-operation free vs. fusion.
Source: Aesculap Implant Systems, LLC
Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems' activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back...
Results from a five-year Investigational Device Exemption study of 261 patients indicate that Aesculap Implant Systems’ activL® lumbar disc more effectively preserved range of motion vs. the ProDisc-L and Charité, first-generation lumbar total disc replacement devices.
Secondary outcomes suggest that activeL was effective in reducing back pain, improving back function and increasing health-related quality of life. Further, at five years, 95% of activL subjects were re-operation free vs. fusion.
Source: Aesculap Implant Systems, LLC
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.